266 related articles for article (PubMed ID: 31208363)
1. Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures.
Li J; Halfter K; Zhang M; Saad C; Xu K; Bauer B; Huang Y; Shi L; Mansmann UR
BMC Cancer; 2019 Jun; 19(1):600. PubMed ID: 31208363
[TBL] [Abstract][Full Text] [Related]
2. Exploiting receptor tyrosine kinase co-activation for cancer therapy.
Tan AC; Vyse S; Huang PH
Drug Discov Today; 2017 Jan; 22(1):72-84. PubMed ID: 27452454
[TBL] [Abstract][Full Text] [Related]
3. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q
Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140
[TBL] [Abstract][Full Text] [Related]
4. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
Sheffels E; Kortum RL
J Med Chem; 2021 May; 64(10):6566-6568. PubMed ID: 33961431
[TBL] [Abstract][Full Text] [Related]
5. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.
Altai M; Orlova A; Tolmachev V
Curr Pharm Des; 2014; 20(14):2275-92. PubMed ID: 24025099
[TBL] [Abstract][Full Text] [Related]
7. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer.
Jin N; Bi A; Lan X; Xu J; Wang X; Liu Y; Wang T; Tang S; Zeng H; Chen Z; Tan M; Ai J; Xie H; Zhang T; Liu D; Huang R; Song Y; Leung EL; Yao X; Ding J; Geng M; Lin SH; Huang M
Nat Commun; 2019 Jun; 10(1):2701. PubMed ID: 31221965
[TBL] [Abstract][Full Text] [Related]
8. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinases and targeted cancer therapeutics.
Takeuchi K; Ito F
Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinases as targets for anticancer drugs.
Zwick E; Bange J; Ullrich A
Trends Mol Med; 2002 Jan; 8(1):17-23. PubMed ID: 11796262
[TBL] [Abstract][Full Text] [Related]
12. Exploratory drug discovery in breast cancer patients: A multimodal deep learning approach to identify novel drug candidates targeting RTK signaling.
Karampuri A; Kundur S; Perugu S
Comput Biol Med; 2024 May; 174():108433. PubMed ID: 38642491
[TBL] [Abstract][Full Text] [Related]
13. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
Tolmachev V; Stone-Elander S; Orlova A
Lancet Oncol; 2010 Oct; 11(10):992-1000. PubMed ID: 20667780
[TBL] [Abstract][Full Text] [Related]
14. The role of RICTOR downstream of receptor tyrosine kinase in cancers.
Jebali A; Dumaz N
Mol Cancer; 2018 Feb; 17(1):39. PubMed ID: 29455662
[TBL] [Abstract][Full Text] [Related]
15. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
Dussault I; Bellon SF
Anticancer Agents Med Chem; 2009 Feb; 9(2):221-9. PubMed ID: 19199866
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
Kleczko EK; Heasley LE
Mol Cancer; 2018 Feb; 17(1):60. PubMed ID: 29458371
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers.
Sharma PS; Sharma R; Tyagi T
Curr Pharm Des; 2009; 15(7):758-76. PubMed ID: 19275641
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinase inhibitors in cancer.
Ebrahimi N; Fardi E; Ghaderi H; Palizdar S; Khorram R; Vafadar R; Ghanaatian M; Rezaei-Tazangi F; Baziyar P; Ahmadi A; Hamblin MR; Aref AR
Cell Mol Life Sci; 2023 Mar; 80(4):104. PubMed ID: 36947256
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel inhibitors of DDR1 against idiopathic pulmonary fibrosis by integrative transcriptome meta-analysis, computational and experimental screening.
Chen C; Deng J; Yu X; Wu F; Men K; Yang Q; Zhu Y; Liu X; Jiang Q
Mol Biosyst; 2016 Apr; 12(5):1540-51. PubMed ID: 26956955
[TBL] [Abstract][Full Text] [Related]
20. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
